Splenectomy for severe autoimmune cytopenias after allogenic stem cell transplantation: case report.
Autoimmune cytopenias are rare but serious complications after hematopoietic stem cell transplantation (HSCT). We per-formed splenectomy in 2 patients who had severe autoimmune cytopenias after allogeneic HSCT (allo-HSCT) that were resist-ant to immunosuppressive treatment. The first patient underwent unrelated allo-HSCT for chronic granulocytic leukemia(CGL) in July 2000. Seven months later, red blood cell and platelet counts went down. The results of a direct Coombs test were intermittently positive. The patient was resistant to therapy with steroids and high-dose immunoglobulin. After a splenectomy was performed in February 2001, the hemoglobin concentration and platelet count improved. Her blood counts remained stable, with a hemoglobin level of approximately 110 g/L and a platelet count >100 x 109/L. She continued therapy with itraconazole, valacyclovir, and penicillin. Some months later, the patient was readmitted for fulminant septic infection, which had a fatal outcome. The second patient underwent related allo-SCT for CGL in January 2003. Seven months later, he was readmitted for intraocular bleeding accompanied by severe thrombocytopenia with antiplatelet antibodies. The patient was resistant to steroid and high-dose immunoglobulin therapy. A splenectomy was performed in September 2003. His platelet count normalized and remains stable. The patient continues therapy with itraconazole, valacyclovir, and penicillin and has not experienced any serious infection. We assume that splenectomy is an effective treatment for resistant immune cytopenias after allo-HSCT. However, severe late infections can compromise the outcome.
Proleznik
Irena
I
Department of Haematology, University Clinical Centre Ljubljana, Slovenia. irena.zupan@kclj.si
Prentice
Hugh Grant
HG
Pretnar
Joze
J
Zver
Samo
S
Cernelc
Peter
P
D000328:Adult; D000740:Anemia / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000209:etiology / Q000628:therapy*; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D008297:Male; D008875:Middle Aged; D013156:Splenectomy; D033581:Stem Cell Transplantation; D013256:Steroids / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D007136:Immunoglobulins; D013256:Steroids